Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.34.3392PMID 21768459PMCID PMC3158599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

  2009cited by this paper
• Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009influential reference
• Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

  2008cited by this paper
• Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.

  2008cited by this paper
• Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group

  2008cited by this paper
• Disease control intervals in high‐risk neuroblastoma

  2008cited by this paper
• Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

  2007cited by this paper
• Neuroblastoma in adolescents

  2006cited by this paper
• Survival after relapse in children with solid tumors: A follow‐up study from the Italian off‐therapy registry

  2006cited by this paper
• Survival after recurrence of Ewing's sarcoma family of tumors.

  2005cited by this paper
• Factors Influencing Survival in Children With Recurrent Neuroblastoma

  2004cited by this paper
• Chronic neuroblastoma

  2002cited by this paper
• Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

  2001cited by this paper
• Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey".

  2001cited by this paper
• Neuroblastoma in adults and adolescents: an indolent course with poor survival.

  1998cited by this paper
• Survival Trees by Goodness of Split

  1993cited by this paper
• Exponential survival trees.

  1989cited by this paper
• Regression Trees for Censored Data

  1988cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

  1976cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Current treatment strategies for first relapse of high-risk neuroblastoma.

  2026cites this paper
• Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk

  2026cites this paper
• A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

  2026cites this paper
• Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy

  2026influential citation
• Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons

  2026cites this paper
• Case Report: Complete remission in a neonate with high-risk neuroblastoma harboring MYCN amplification and 1p deletion: a case for aggressive early intervention, and literature review

  2026cites this paper
• Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison

  2025cites this paper
• A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors

  2025cites this paper
• NONO as a Sensor of Intracellular Oxidation: Relevance to Neuroblastoma Cell Death

  2025cites this paper
• The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

  2025cites this paper
• NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosis

  2025cites this paper
• Recommended phase 2 dose for abemaciclib in combination with irinotecan and temozolomide in pediatric and young adult patients with relapsed/refractory solid tumors: Results from JPCS study (Part A)

  2025cites this paper
• A Nomogram for Predicting Cancer-Specific Survival of Neuroblastoma in Children < 2 Years Old: A SEER Database Analysis

  2025cites this paper
• Preoperative CT-based radiomics nomogram for progression-free survival prediction in pediatric posterior mediastinal malignancies

  2025cites this paper
• Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma

  2025cites this paper
• Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.

  2025cites this paper
• From Local to International Approach: Prognostic Factors and Treatment Outcomes in Neuroblastoma—A 30-Year Single-Center Retrospective Analysis

  2025cites this paper
• “Complication without context? Rethinking outcome attribution in pediatric oncologic surgery”

  2025cites this paper
• Microbiome in Neuroblastoma: A Virgin Island in the World of Onco-Microbiome

  2025cites this paper
• Ultrasound‐guided interstitial photothermal therapy generates improved treatment responses in a 9464D model of neuroblastoma

  2025cites this paper
• Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study

  2025cites this paper
• Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes

  2025cites this paper
• International neuroblastoma risk group consortium: a model of a networking for rare cancers.

  2025cites this paper
• Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module

  2024cites this paper
• The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma

  2024cites this paper
• Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma

  2024influential citation
• Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers

  2024cites this paper
• Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials

  2024influential citation
• Effects and mechanisms of puerarin against neuroblastoma: insights from bioinformatics and in vitro experiments

  2024cites this paper
• Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

  2024cites this paper
• Family Recall of and Response to Germline Pathologic Variants Found on Paired Tumor-Germline Sequencing in Pediatric Oncology

  2024cites this paper
• Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors

  2024cites this paper
• Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.

  2024cites this paper
• The causal relationship between gut microbiota and neuroblastoma: a bidirectional Mendelian randomization analysis and meta-analysis

  2024cites this paper
• Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

  2024cites this paper
• Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram

  2024cites this paper
• The Race Against Time for the Enhancement of African National Strategic Plans in the Neuroblastoma Research Heterogeneity

  2024cites this paper
• SAP30, a novel autophagy regulatory gene in neuroblastoma

  2024cites this paper
• Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas

  2024cites this paper
• Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade

  2024cites this paper
• Potential Cause-and-Effect Relationship between Gut Microbiota and Childhood Neuroblastoma: A Mendelian Randomization Analysis

  2024cites this paper
• Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma

  2024cites this paper
• Whole exome sequencing in relapsed or refractory childhood cancer: case series

  2024cites this paper
• Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients

  2024cites this paper
• Neuroblastoma

  2023cites this paper
• Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus

  2023cites this paper
• Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors

  2023cites this paper
• Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma

  2023cites this paper
• High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma

  2023cites this paper
• Multimodality treatment for recurrent neuroblastoma in the central nervous system

  2023cites this paper
• Precision Oncology in Pediatric Cancer Surgery.

  2023cites this paper
• Integrative analysis of CRISPR screening and gene expression data identifies a three-gene prognostic model associated with immune microenvironment in neuroblastoma

  2023cites this paper
• The prognostic and predictive value of plasma D-dimer in children with neuroblastoma: a 7-year retrospective analysis at a single institution

  2023cites this paper
• Late Relapse in Neuroblastoma: Case Report and Review of the Literature.

  2023cites this paper
• Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series

  2023cites this paper
• Triple Therapy with Metformin, Ketogenic Diet, and Metronomic Cyclophosphamide Reduced Tumor Growth in MYCN-Amplified Neuroblastoma Xenografts

  2023influential citation
• Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

  2023cites this paper
• Identification of a novel gene signature for neuroblastoma differentiation using a Boolean implication network

  2023cites this paper
• A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma

  2023cites this paper
• A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients.

  2023cites this paper
• RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease

  2023cites this paper
• Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma

  2023cites this paper
• Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

  2022cites this paper
• Revealing the heterogeneity in neuroblastoma cells via nanopillar-guided subnuclear deformation.

  2022cites this paper
• Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

  2022cites this paper
• Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation.

  2022cites this paper
• Loss of ALK hotspot mutations in relapsed neuroblastoma

  2022cites this paper
• Immune checkpoint molecules in neuroblastoma: A clinical perspective.

  2022cites this paper
• Interstitial Photothermal Therapy Generates Durable Treatment Responses in Neuroblastoma

  2022cites this paper
• The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions

  2022cites this paper
• Risk Factors Associated with Metastatic Site Failure in Patients with High-Risk Neuroblastoma

  2022cites this paper
• TTF1 suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis

  2022cites this paper
• Advances in liquid biopsy in neuroblastoma

  2022cites this paper
• ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma

  2022cites this paper
• Identification of Key Genes Associated with Risk and Prognosis of Neuroblastoma

  2022cites this paper
• Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

  2022cites this paper
• Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020

  2022cites this paper
• Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients

  2022cites this paper
• NSUN2 gene rs13181449 C>T polymorphism reduces neuroblastoma risk.

  2022cites this paper
• A practical solution to estimate the sample size required for clinical prediction models generated from observational research on data

  2022cites this paper
• Minimal residual disease detected by droplet digital PCR in peripheral blood stem cell grafts has a prognostic impact on high-risk neuroblastoma patients

  2022cites this paper
• Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group

  2022cites this paper
• Exosomes in Neuroblastoma Biology, Diagnosis, and Treatment

  2022cites this paper
• Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

  2022cites this paper
• Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

  2022cites this paper
• Neuroblastome

  2022cites this paper
• LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex

  2022cites this paper
• Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

  2022cites this paper
• miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma

  2022cites this paper
• The Efficacy Of Autologous Stem Cell Transplants To Treat High Risk Neuroblastoma

  2022cites this paper
• Nanomedicines and cell-based therapies for embryonal tumors of the nervous system.

  2022cites this paper
• My, what a big thymus you have! Neonate/infant mediastinal masses

  2022cites this paper
• Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma

  2022cites this paper
• Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

  2022cites this paper
• Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases

  2022cites this paper
• Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma

  2022cites this paper
• Journal of Stem Cell Research The Efficacy of Autologous Stem Cell Transplants to Treat High Risk Neuroblastoma

  2022cites this paper
• A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma

  2022cites this paper
• Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

  2021cites this paper
• Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies

  2021cites this paper